Robot-assisted surgical systems market seen reaching $45.45 billion by 2035

Market Research Future says the global robot-assisted surgical systems market will grow from $13.65 billion in 2026 to $45.45 billion by 2035, driven by outpatient procedure migration, AI-enabled guidance and lower-cost Asian platforms. The outlook points to faster adoption in hospitals and ambulatory surgery centers as reimbursement, autonomy rules and software-driven models reshape procurement.

Why it matters: - The market is moving from a premium hospital purchase to a broader care-delivery platform. - Lower-cost systems, outpatient migration and AI-assisted surgery could expand robotic procedures across more hospitals, specialty centers and ambulatory surgery centers. - The shift matters for payers and providers because the business case now ties to shorter stays, fewer complications and higher-throughput outpatient care.

What happened: - Market Research Future projects the global robot-assisted surgical systems market will rise from $13.65 billion in 2026 to $45.45 billion by 2035. - The forecast implies a 14.3% compound annual growth rate for 2026-2035. - The market base was estimated at $12.04 billion in 2025. - The firm identified outpatient procedure migration, AI-enabled intraoperative guidance and domestic Asian platform cost disruption as the main growth drivers. - A free sample is available here. - The full report is available here.

The details: - The U.S. Centers for Medicare & Medicaid Services expanded the Ambulatory Surgical Center covered list in 2024 with 41 newly eligible surgical codes. - The FDA implemented a three-tier autonomy framework in 2024 for AI-enabled decision support during procedures. - The report says the top five vendors committed an estimated $1.2 billion in additional R&D within a year of that framework. - China’s National Medical Products Administration cleared four domestically developed robotic platforms between 2023 and 2025. - The report says those clears intensified price competition across Asia-Pacific and helped compress average selling prices by 25% to 40%. - Early-adopter health systems report AI-enhanced preoperative planning and intraoperative analytics reduced complication rates by 15% to 22% versus conventional laparoscopy. - Machine-learning models trained on more than 3 million surgical datasets are said to predict optimal port placement and tissue resection margins with accuracy above 94% in multi-center validation studies. - The report says robotic-assisted procedures reduce average hospitalization by 1.8 to 2.4 days compared with open surgery, saving payers about $12,000 to $18,000 per patient. - The move toward subscription software and services is lowering upfront acquisition barriers from seven-figure capital outlays to annual license agreements. - Ambulatory surgical centers and community clinics are shifting toward per-procedure leasing arrangements to match lower operating costs and higher patient throughput.

Between the lines: - The market is increasingly being shaped by reimbursement policy, not just clinical preference. - CMS coverage changes, value-based contracts and outpatient economics are making robotic systems easier to justify financially. - The report points to a broader transition from hardware sales to software, analytics and service revenue. - That shift favors vendors with large installed bases, cloud-linked platforms and recurring revenue models. - Asia-Pacific cost competition is also pressuring incumbents to defend share with lower prices and more integrated ecosystems. - The report’s growth case assumes hospitals continue to treat robotics as a tool for shorter stays, better outcomes and capacity relief rather than as an elective luxury.

What's next: - The report expects digital surgery ecosystems to become the operating model for robotic-assisted care by 2030. - By 2030, an estimated 35% of newly diagnosed colorectal and gynecologic malignancy patients are projected to receive AI-enhanced staging followed by matched robotic-assisted resection. - Start-ups have raised more than $800 million in venture funding for surgical decision-support tools since 2023. - The FDA’s autonomy framework is expected to keep U.S. AI-enabled platform development aligned with clinical demand. - Continued adoption in ambulatory surgery centers and community hospitals will likely remain a key test of the market’s next phase.

The bottom line: - Robotics in surgery is shifting from a high-end specialty category to a broader, AI-linked care platform with reimbursement and software economics driving the next leg of growth.